Sobi-Invitation to Conference Call today at 2.30 pm CET

Financial analysts and media are invited to a telephone conference today at 2.30 p.m. CET following the joint release with Biogen Idec of the top-line results from the phase 3 study investigating long-lasting recombinant factor IX fusion protein in Hemophilia B. The call will be hosted by CEO Geoffrey McDonough. Slides used in the presentation will be available on prior to the telephone conference. Details for participation Please call: Sweden: +46 (0)8 505 598 45 UK: +44 (0)207 108 63 03 US: +1 866 676 58 69 Yours sincerely, Åsa Stenqvist, VP Communications and IR (Interim) Phone: +46 8 697 21 88 Swedish Orphan Biovitrum (Sobi) Sobi is an international healthcare company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients. The product portfolio is primarily focused on Inflammation and Genetic diseases, with three late stage biological development projects within hemophilia and neonatology. Sobi also markets more than 40 products for companies in the specialty and rare disease space. In 2011, Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at Invitation TC September 26, 2012 in pdf format: This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE [HUG#1643713]